Theraflu LAR pills №16

Dosage Form:  

lozenges

Composition (per 1 tablet):

Active ingredients: benzoxonium chloride 1 mg, Lidocaine hydrochloride 1 mg;

Excipients:Sorbitol 1000 mg, microcrystalline cellulose 20 mg, macrogol 6000 25 mg, corn starch 55 mg, sodium saccharinate 4 mg, sodium chloride 10 mg, citric acid
5 mg, Magnesium stearate 1 mg, orange flavoring 40 mg.

One pill contains 1 g of sorbitol sweetener, which corresponds to approximately 17 kJ
(4 kcal).

Pharmacotherapeutic group:

Antiseptic.

Pharmacological properties:

Benzoxonium chloride - a quaternary ammonium salt (N-benzyl N-dodecyl N, N-di (2-hydroxyethyl) ammonium chloride), due to its cationic structure, has membrane-active activity and has a pronounced antibacterial action against gram-positive and, to a lesser extent, gram-negative microorganisms. Benzoxonium also has antifungal and antiviral activity against membrane viruses (including viruses of influenza, parainfluenza and herpes).

Lidocaine is a local anesthetic that during inflammation reduces pain in the throat when swallowing.

Pharmacokinetics:

Benzoksoniya chloride is practically not absorbed.In humans, approximately 1% of the administered dose is detected in the urine, the concentration of the substance in the blood is not detected. Not detected accumulation of substances in the tissues of the body.

Lidocaine is absorbed by oral administration and through the mucous membrane of the oral cavity. Metabolized when the "first" passage through the liver, when administered orally, its bioavailability is approximately 35%. Metabolites are excreted in the urine, less than 10% of the substance excreted unchanged.

Indications for use:

Infections of the oral cavity and pharynx: pharyngitis, laryngitis, catarrhal tonsillitis, stomatitis, ulcerative gingivitis.

As an aid, chronic tonsillitis.

Contraindications:

Hypersensitivity to lidocaine or ammonia compounds.

The use of the drug is not recommended for children under 4 years of age, during the first trimeter of pregnancy and during breastfeeding.

Use of the drug during pregnancy and during breastfeeding.

The effects of the drug on reproductive function and fetal development in the experiment were not found. Controlled studies with the participation of pregnant women have not been conducted, and therefore should not use Theraflu^® LAR during pregnancy, especially in the first trimester. There is no clinical data on the penetration of the active ingredient into breast milk. However, the drug is not recommended for use during breastfeeding.

Doses and method of use:

Inside. A single dose - 1 pill every 2-3 hours.If symptoms are expressed, take 1 pill every 1-2 hours. The pill should slowly dissolve in the mouth.

The daily dose should not exceed 10 tablets.

Children: drug Theraflu^® LAR can be applied to children from 4 years, with 1 pill every 2-3 hours. The daily dose should not exceed 6 tablets.

Side effects:

Sometimes when applying Theraflu^® LAR observed local irritation, which is temporary. Allergic reactions are rare.

During the use of the drug for more than 2 weeks, a reversible brown coloration of the tongue or teeth may be observed.

Overdose:

Accidental intake of large doses of Theraflu^® LAR, like other ammonia compounds, can cause nausea or vomiting. In case of overdose, it is recommended to drink milk or eat egg whites whipped in water.

Lidocaine content in Theraflu^® LAR is insignificant and cannot cause serious symptoms of overdose.

Interactions:

The effectiveness of benzoxonium chloride is reduced while taking anionic agents, such as toothpaste.

Alcohol increases the absorption of benzoxonium chloride (alcohol should be avoided during therapy).

Effect of the drug on the ability to drive vehicles and control mechanisms:

does not affect.

Storage conditions:

Store in a dry place at temperatures below 30 °. Keep out of reach of children.

Shelf life:

Do not use the drug after the expiration date printed on the package.

Pharmacy sales conditions:

Over the counter.